Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 4/20 | 0.88 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.88 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.88 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.88 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.88 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.88 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491814 | 1.00 | PSEN1 (0.88) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL491353 | 0.94 | PSEN1 (0.86) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL491331 | 0.94 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL491938 | 0.94 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL491340 | 0.94 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL491339 | 0.91 | PSEN1 (0.90) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL491402 | 0.91 | PSEN1 (0.90) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10077820 | 0.90 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10077864 | 0.90 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL491302 | 0.90 | PSEN1 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215043-B1 | CARBON LINKED MODULATORS OF Y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| WO-2009052334-A1 | CARBON LINKED MODULATORS OF Y-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105288-A1 | CARBON LINKED MODULATORS OF gamma-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2007124351-A1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105288-A1 | CARBON LINKED MODULATORS OF gamma-SECRETASE | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 7/4885APH1B 6/4885 |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 5/4885APH1B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.